Background
Phase III, open-label RCT. 328 patients aged ≤18 with newly diagnosed mature B-cell NHL (Burkitt lymphoma, DLBCL, PMBCL) stage III–IV or any stage with CNS involvement. All received the FAB/LMB96 chemoimmunotherapy backbone. Tested adding rituximab to standard pediatric LMB-based chemotherapy in children and adolescents.
Interventions and follow up
Arm A: Rituximab 375mg/m² IV (6 doses across induction and consolidation) added to standard FAB/LMB96 chemotherapy
Arm B: Standard FAB/LMB96 chemotherapy alone (cyclophosphamide + vincristine + prednisone + methotrexate + doxorubicin + cytarabine ± intrathecal therapy; backbone by risk group)
Primary endpoint: Event-free survival
Median follow-up: 3.9 years
Arm B: Standard FAB/LMB96 chemotherapy alone (cyclophosphamide + vincristine + prednisone + methotrexate + doxorubicin + cytarabine ± intrathecal therapy; backbone by risk group)
Primary endpoint: Event-free survival
Median follow-up: 3.9 years
Results
3-year EFS: 93.9% vs 82.3%, HR 0.32, 95% CI 0.18–0.57, P<.001
3-year OS: 95.1% vs 87.3%, HR 0.36, 95% CI 0.19–0.68, P=.001
Absolute EFS improvement: +11.6 percentage points
3-year OS: 95.1% vs 87.3%, HR 0.36, 95% CI 0.19–0.68, P=.001
Absolute EFS improvement: +11.6 percentage points
Adverse events
Infectious (rituximab vs no rituximab): Grade 3–4 infections 28.0% vs 20.9%; febrile neutropenia 46.6% vs 38.9%.
Other: No excess serious infusion reactions; rituximab-associated hypogammaglobulinemia monitored but not a major concern at ~4-year follow-up.
Other: No excess serious infusion reactions; rituximab-associated hypogammaglobulinemia monitored but not a major concern at ~4-year follow-up.
Conclusions
Adding rituximab to LMB-based chemotherapy significantly improved both EFS (93.9% vs 82.3%) and OS (95.1% vs 87.3%) in children and adolescents with high-risk mature B-cell NHL, establishing rituximab + LMB as the new standard of care in this pediatric population.
Key Limitations
Pediatric rituximab dosing/scheduling differs from adult protocols — results are not directly comparable to adult R-CHOP data. Long-term follow-up for late effects (hypogammaglobulinemia, infection risk, secondary malignancies) remains ongoing. The study enrolled across developed and resource-limited settings with some protocol deviations. The high-risk/CNS (group C) cohort had fewer patients and shorter follow-up.
Clinical Context
This trial establishes rituximab + LMB-based chemotherapy as the standard frontline regimen for pediatric/adolescent high-risk mature B-cell NHL worldwide, mirroring the adult paradigm from LNH-98.5 (GELA). The FDA and EMA approved rituximab in combination with chemotherapy for previously untreated pediatric mature B-cell NHL based on these data. It is a frequently tested board topic as the pediatric counterpart to adult R-CHOP.